1. Articles in category: Treatment

    1-24 of 89 1 2 3 4 »
    1. Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Immunoassays for the quantification of ALK and phosphorylated ALK support the evaluation of on-target ALK inhibitors in neuroblastoma.

      Mol Oncol. 2017 Apr 22;:

      Authors: Tucker ER, Tall JR, Danielson LS, Gowan S, Jamin Y, Robinson SP, Banerji U, Chesler L

      Read Full Article
      Mentions: ALK
    2. Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.

      Tolcapone induces oxidative stress leading to apoptosis and inhibition of tumor growth in Neuroblastoma.

      Cancer Med. 2017 Apr 21;:

      Authors: Maser T, Rich M, Hayes D, Zhao P, Nagulapally AB, Bond J, Saulnier Sholler G

      Abstract Catechol-O-methyltransferase (COMT) is an enzyme that inactivates dopamine and other catecholamines by O-methylation.

      Read Full Article
    3. Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models.

      Elife. 2017 Apr 20;6:

      Authors: Wang HQ, Halilovic E, Li X, Liang J, Cao Y, Rakiec DP, Ruddy DA, Jeay S, Wuerthner JU, Timple N, Kasibhatla S, Li N, Williams JA, Sellers WR, Huang A, Li F

      Read Full Article
      Mentions: ALK MYCN
    4. TIAM1 variants improve clinical outcome in neuroblastoma.

      TIAM1 variants improve clinical outcome in neuroblastoma.

      Oncotarget. 2017 Apr 03;:

      Authors: Sanmartín E, Yáñez Y, Fornés-Ferrer V, Zugaza JL, Cañete A, Castel V, Font de Mora J

      Abstract Identification of tumor driver mutations is crucial for improving clinical outcome using a personalized approach to the treatment of cancer.

      Read Full Article
      Mentions: Treatment ALK MYCN
    5. Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Novel targeted therapy for neuroblastoma: Silencing the MXD3 gene using siRNA.

      Pediatr Res. 2017 Apr 18;:

      Authors: Duong C, Yoshida S, Chen C, Barisone G, Diaz E, Li Y, Beckett L, Chung J, Antony R, Nolta J, Nitin N, Satake N

      Abstract BACKGROUND: Neuroblastoma is the second most common extracranial cancer in children.

      Read Full Article
    6. Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Modulation of interactions of neuroblastoma cell lines with extracellular matrix proteins affects their sensitivity to treatment with the anti-GD2 ganglioside antibody 14G2a.

      Int J Oncol. 2017 Apr 07;:

      Authors: Horwacik I, Rokita H

      Abstract Children diagnosed with high risk neuroblastoma have poor prognosis which stimulates efforts to broaden therapies of the neoplasm. GD2-ganglioside (GD2) marks neuroblastoma cells and is a target for monoclonal antibodies.

      Read Full Article
      Mentions: Antibody Treatment
    7. Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Dinutuximab for maintenance therapy in pediatric neuroblastoma.

      Am J Health Syst Pharm. 2017 Apr 15;74(8):563-567

      Authors: McGinty L, Kolesar J

      Abstract PURPOSE: The pharmacology, clinical efficacy, safety, dosage and administration, and role in therapy of dinutuximab for the treatment of high-risk pediatric neuroblastoma are reviewed.

      Read Full Article
      Mentions: Treatment
    8. Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Residual tumor in cases of intermediate-risk neuroblastoma did not influence the prognosis.

      Jpn J Clin Oncol. 2016 Jul;46(7):661-6

      Authors: Iehara T, Yagyu S, Tsuchiya K, Kuwahara Y, Miyachi M, Tajiri T, Sugimoto T, Sawada T, Hosoi H

      Abstract BACKGROUND: It remains unclear whether a residual tumor mass following therapy influences the prognosis of neuroblastoma.

      Read Full Article
      Mentions: MIBG
    9. Orphan designation: Iodine (131I) murine IgG1 monoclonal antibody against CD276, for the: Treatment of neuroblastoma

      Review of designation Orphan designation On 27 February 2017, orphan designation (EU/3/17/1839) was granted by the European Commission to Y-mAbs Therapeutics A/S, Denmark, for iodine ( 131 I) murine IgG1 monoclonal antibody against CD276 (also known as 131 I-mu8H9) for the treatment of neuroblastoma. What is neuroblastoma? Neuroblastoma is a cancer of certain nerve cells which is usually seen as a lump in the abdomen or around the spine.

      Read Full Article
      Mentions: Antibody Treatment
    10. Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      Biomarker May Identify Neuroblastoma Patients Most Likely to Benefit from Immunotherapy

      ​WASHINGTON — Among patients with high-risk neuroblastoma, those who had a certain combination of genotypes gained substantial benefit from adding immunotherapy to isotretinoin treatment, while it is uncertain whether those who lacked the combination gained benefit from immunotherapy, according to results from a randomized phase III clinical trial presented here at the AACR Annual Meeting 2017, April 1-5.

      Read Full Article
    11. Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma.

      Mol Ther Oncolytics. 2017 Mar 17;4:67-76

      Authors: Gutova M, Goldstein L, Metz M, Hovsepyan A, Tsurkan LG, Tirughana R, Tsaturyan L, Annala AJ, Synold TW, Wan Z, Seeger R, Anderson C, Moats RA, Potter PM, Aboody KS

      Read Full Article
    12. ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      ICR scientists awarded £1.5m precision medicine funding for targeted, less toxic childhood cancer treatments

      Scientists from The Institute of Cancer Research, London, have been awarded £1.5 million by the charity Children with Cancer UK to advance precision medicine in the UK and improve cancer treatment for children and young adults.

      Read Full Article
      Mentions: Treatment
    13. Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo.

      Androgen Receptor Regulates the Growth of Neuroblastoma Cells in vitro and in vivo.

      Front Neurosci. 2017;11:116

      Authors: Sun J, Wang D, Guo L, Fang S, Wang Y, Xing R

      Abstract Background: Neuroblastoma is the most common extracranial tumors in children. At present about the true etiology of neuroblastoma is unclear and many studies have tried to find effective treatments for these primary malignant tumors.

      Read Full Article
    14. Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Feasibility, toxicity and response of upfront metaiodobenzylguanidine therapy therapy followed by German Pediatric Oncology Group Neuroblastoma 2004 protocol in newly diagnosed stage 4 neuroblastoma patients.

      Eur J Cancer. 2017 Mar 19;76:188-196

      Authors: Kraal KC, Bleeker GM, van Eck-Smit BL, van Eijkelenburg NK, Berthold F, van Noesel MM, Caron HN, Tytgat GA

      Read Full Article
      Mentions: GPOH MIBG
    15. Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Bronchiectasis following treatment for high-risk neuroblastoma: A case series.

      Pediatr Blood Cancer. 2017 Mar 10;:

      Authors: Adams M, Traunecker H, Doull I, Cox R

      Abstract High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors.

      Read Full Article
    16. Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus

      Alerts Cancer Therapy: Preclinical Safe and Effective Treatment of Experimental Neuroblastoma and Glioblastoma Using Systemically Delivered Triple MicroRNA-Detargeted Oncolytic Semliki Forest Virus Mohanraj Ramachandran , Di Yu , Matheus Dyczynski , Sathishkumar Baskaran , Lei Zhang , Aleksei Lulla , Valeria Lulla , Sirle Saul , Sven Nelander , Anna Dimberg , Andres Merits , Justyna Leja-Jarblad and Magnus Essand Mohanraj Ramachandran PDF Abstract Background: Glioblastoma multiforme and high-risk neuroblastoma are cancers with poor outcome. Immunotherapy in the form of neurotropic oncolytic viruses is a promising therapeutic approach for these malignancies. Here we evaluate the oncolytic capacity of the neurovirulent and partly IFNβ-resistant Semliki Forest virus (SFV)-4 in glioblastoma multiformes ...

      Read Full Article
    17. Bronchiectasis following treatment for high-risk neuroblastoma: A case series

      High-risk (HR) neuroblastoma remains a very challenging disease to treat and long-term cure is only possible with intensive, multimodal treatment including chemotherapy, high-dose therapy, radiotherapy, surgery, and immunotherapy. As a result, treatment-related morbidity and late effects are common in survivors. This report outlines a case series of six patients who developed a chronic productive cough following treatment for HR neuroblastoma.

      Read Full Article
    18. Polyphyllin D, a steroidal saponin in Paris polyphylla, induces apoptosis and necroptosis cell death of neuroblastoma cells.

      Polyphyllin D, a steroidal saponin in Paris polyphylla, induces apoptosis and necroptosis cell death of neuroblastoma cells.

      Pediatr Surg Int. 2017 Mar 04;:

      Authors: Watanabe S, Suzuki T, Hara F, Yasui T, Uga N, Naoe A

      Abstract PURPOSE: Neuroblastoma is a refractory pediatric malignant solid tumor. The previous studies demonstrated that Polyphyllin D, the main constituent of Paris polyphylla, a traditional Chinese medicine, exerts an anti-tumor effect on many tumors.

      Read Full Article
      Mentions: Refractory MYCN
    19. Busulfan–melphalan in high-risk neuroblastoma: the 30-year experience of a single institution

      "All patients had a stage 4 neuroblastoma. NMYC amplification was displayed in 24% of the tumors. The hematopoietic support consisted of bone marrow or PBSCs in 46% and 49% of patients, respectively. The 5-year event-free survival and overall survival rates of the whole cohort were 35.1% and 40%, respectively. Age at diagnosis, bone marrow involvement and tumor response after induction chemotherapy were significant prognostic factors. Toxicity was manageable and decreased over time, owing to both PBSC administration and better supportive care. Based on this experience, HD Bu–melphalan (Mel) has been implemented in Europe and compared with Carboplatin–Etoposide ...

      Read Full Article
      Mentions: Bone Marrow
    20. Busulfan-melphalan in high-risk neuroblastoma: the 30-year experience of a single institution.

      "All patients had a stage 4 neuroblastoma. NMYC amplification was displayed in 24% of the tumors. The hematopoietic support consisted of bone marrow or PBSCs in 46% and 49% of patients, respectively. The 5-year event-free survival and overall survival rates of the whole cohort were 35.1% and 40%, respectively. Age at diagnosis, bone marrow involvement and tumor response after induction chemotherapy were significant prognostic factors. Toxicity was manageable and decreased over time, owing to both PBSC administration and better supportive care. Based on this experience, HD Bu-melphalan (Mel) has been implemented in Europe and compared with Carboplatin-Etoposide-Mel in the ...

      Read Full Article
    21. Rapid COJEC Induction Therapy for High-risk Neuroblastoma Patients - Cochrane Review.

      "We identified one relevant randomized controlled trial with 130 participants receiving rapid COJEC and 132 participants receiving standard OPEC/COJEC induction chemotherapy. There was no statistically significant difference between the treatment groups in complete response (risk ratio 0.99, 95% confidence interval 0.71 to 1.38, P=0.94) and treatment-related mortality (risk ratio 1.21, 95% confidence interval 0.33 to 4.39, P=0.77). A statistically significant difference in favor of the standard treatment arm was identified for the following early toxicities: febrile neutropenia, septicemia, and renal toxicity. Conclusion: The differences in complete response and treatment-related ...

      Read Full Article
      Mentions: Chemotherapy
    1-24 of 89 1 2 3 4 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (3 articles) ALK
    2. (2 articles) Antibody
    3. (2 articles) MYCN
    4. (1 articles) Immunotherapy
  4. General Informations in the News

    1. (7 articles) Treatment
    2. (1 articles) Hearing Loss
  5. Treatments in the News

    1. (1 articles) MIBG